Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
People want to trade shares, fine.. Trade them.
People want to gamble then go to a bookies.
Gambling = Avoiding taxes, and not having to pay upfront.
I salute the ones that caused the mayhem over at GME and hopefully the fall out will quickly shut down the likes of gambling options available under the pretence of share dealing and also remove a big chunk of the carnage and mayhem these gamblers inflict when they sell short.
People want to hold shares, then fine. Buy them. :-)
If you do nothing else this evening then listen to this podcast.
www.share-talk.com/avihu-tamir-ceo-of-kanabo-group-plc-knb-l-first-day-of-dealings-interview/
Highlights
– The Company has raised gross proceeds of £6 million through an oversubscribed fundraising;
– Kanabo Research Limited has the only medically-approved vaporisation device, the VapePod®, which provides metered dosages of its proprietary cannabis-based oil formulations;
– Kanabo is already engaged in selling its products as part of a Pilot Scheme and expects to soon be ready to scale up its sales;
– Kanabo’s products are triple-tested for safety, and Kanabo has plans for further safety and efficacy testing on their products;
– Use of Proceeds for the next 12 months include sales & marketing and research & development.
Upon Admission, the Company will acquire Kanabo Research Limited for an initial consideration of £15 million. The initial consideration is being satisfied by the issue of 230,769,210 new ordinary shares in the Company. In conjunction with Admission, the Company has raised gross proceeds of £6.0 million through an oversubscribed fundraising that is comprised of a placing and subscription, at an issue price of 6.5 pence per share. Upon Admission, the Company will have a market capitalisation (at the issue price) of approximately £23.4 million. Peterhouse Capital Limited acted as Broker and SI Capital Limited as Placing Agent to this fundraising.
Avihu Tamir, CEO of Kanabo Group Plc, says:
“We are proud and happy to be listed on London Stock Exchange. I would like to thank Spinnaker Opportunities and the whole transaction team for helping us to reach this goal and to thank new and existing shareholders who have invested in our pioneering endeavour.
We share the enthusiasm shown by the investment community in the UK for this important day. The reaction we have seen since we published our prospectus two weeks ago has been overwhelming. With the support of the FCA and London Stock Exchange, the medical cannabis industry is set to take off in the UK and in Europe, similar to what’s happened in North America in recent times. This is just the beginning”.
Having worked at BAT research where Vapes are being developed, and refined, I find this very interesting and certainly something that cannot be dismissed.
I think cellular is a flop and being punted with a glossy beckham pose.
Synthetic...
For crying out loud, scientists have not broken the coating on understanding the complexities of cannanaboids and now this outfit creating "Synthetic"...
If you do nothing else this evening then listen to this podcast.
I know its for KNB, but with these 2 new IPO's there is nothing wrong in holding both..
Its not a "Them and Us"
Kanabo "KNB" looks at least as exciting and interesting as MXC
The CEO mentions that even 3 times todays price should not be a surprise... :-)
www.share-talk.com/avihu-tamir-ceo-of-kanabo-group-plc-knb-l-first-day-of-dealings-interview/
Highlights
– The Company has raised gross proceeds of £6 million through an oversubscribed fundraising;
– Kanabo Research Limited has the only medically-approved vaporisation device, the VapePod®, which provides metered dosages of its proprietary cannabis-based oil formulations;
– Kanabo is already engaged in selling its products as part of a Pilot Scheme and expects to soon be ready to scale up its sales;
– Kanabo’s products are triple-tested for safety, and Kanabo has plans for further safety and efficacy testing on their products;
– Use of Proceeds for the next 12 months include sales & marketing and research & development.
Upon Admission, the Company will acquire Kanabo Research Limited for an initial consideration of £15 million. The initial consideration is being satisfied by the issue of 230,769,210 new ordinary shares in the Company. In conjunction with Admission, the Company has raised gross proceeds of £6.0 million through an oversubscribed fundraising that is comprised of a placing and subscription, at an issue price of 6.5 pence per share. Upon Admission, the Company will have a market capitalisation (at the issue price) of approximately £23.4 million. Peterhouse Capital Limited acted as Broker and SI Capital Limited as Placing Agent to this fundraising.
Avihu Tamir, CEO of Kanabo Group Plc, says:
“We are proud and happy to be listed on London Stock Exchange. I would like to thank Spinnaker Opportunities and the whole transaction team for helping us to reach this goal and to thank new and existing shareholders who have invested in our pioneering endeavour.
We share the enthusiasm shown by the investment community in the UK for this important day. The reaction we have seen since we published our prospectus two weeks ago has been overwhelming. With the support of the FCA and London Stock Exchange, the medical cannabis industry is set to take off in the UK and in Europe, similar to what’s happened in North America in recent times. This is just the beginning”.
Try multiplying todays price by X 3... Thats what the CEO reckons..
If you do nothing else this evening then listen to this podcast.
The CEO mentions that even 3 times todays price should not be a surprise... :-)
www.share-talk.com/avihu-tamir-ceo-of-kanabo-group-plc-knb-l-first-day-of-dealings-interview/
Highlights
– The Company has raised gross proceeds of £6 million through an oversubscribed fundraising;
– Kanabo Research Limited has the only medically-approved vaporisation device, the VapePod®, which provides metered dosages of its proprietary cannabis-based oil formulations;
– Kanabo is already engaged in selling its products as part of a Pilot Scheme and expects to soon be ready to scale up its sales;
– Kanabo’s products are triple-tested for safety, and Kanabo has plans for further safety and efficacy testing on their products;
– Use of Proceeds for the next 12 months include sales & marketing and research & development.
Upon Admission, the Company will acquire Kanabo Research Limited for an initial consideration of £15 million. The initial consideration is being satisfied by the issue of 230,769,210 new ordinary shares in the Company. In conjunction with Admission, the Company has raised gross proceeds of £6.0 million through an oversubscribed fundraising that is comprised of a placing and subscription, at an issue price of 6.5 pence per share. Upon Admission, the Company will have a market capitalisation (at the issue price) of approximately £23.4 million. Peterhouse Capital Limited acted as Broker and SI Capital Limited as Placing Agent to this fundraising.
Avihu Tamir, CEO of Kanabo Group Plc, says:
“We are proud and happy to be listed on London Stock Exchange. I would like to thank Spinnaker Opportunities and the whole transaction team for helping us to reach this goal and to thank new and existing shareholders who have invested in our pioneering endeavour.
We share the enthusiasm shown by the investment community in the UK for this important day. The reaction we have seen since we published our prospectus two weeks ago has been overwhelming. With the support of the FCA and London Stock Exchange, the medical cannabis industry is set to take off in the UK and in Europe, similar to what’s happened in North America in recent times. This is just the beginning”.
Used Interactive Investor...
Now live and no problems trading..
If you do nothing else this evening then listen to this podcast.
The CEO mentions that even 3 times todays price should not be a surprise... :-)
www.share-talk.com/avihu-tamir-ceo-of-kanabo-group-plc-knb-l-first-day-of-dealings-interview/
Highlights
– The Company has raised gross proceeds of £6 million through an oversubscribed fundraising;
– Kanabo Research Limited has the only medically-approved vaporisation device, the VapePod®, which provides metered dosages of its proprietary cannabis-based oil formulations;
– Kanabo is already engaged in selling its products as part of a Pilot Scheme and expects to soon be ready to scale up its sales;
– Kanabo’s products are triple-tested for safety, and Kanabo has plans for further safety and efficacy testing on their products;
– Use of Proceeds for the next 12 months include sales & marketing and research & development.
Upon Admission, the Company will acquire Kanabo Research Limited for an initial consideration of £15 million. The initial consideration is being satisfied by the issue of 230,769,210 new ordinary shares in the Company. In conjunction with Admission, the Company has raised gross proceeds of £6.0 million through an oversubscribed fundraising that is comprised of a placing and subscription, at an issue price of 6.5 pence per share. Upon Admission, the Company will have a market capitalisation (at the issue price) of approximately £23.4 million. Peterhouse Capital Limited acted as Broker and SI Capital Limited as Placing Agent to this fundraising.
Avihu Tamir, CEO of Kanabo Group Plc, says:
“We are proud and happy to be listed on London Stock Exchange. I would like to thank Spinnaker Opportunities and the whole transaction team for helping us to reach this goal and to thank new and existing shareholders who have invested in our pioneering endeavour.
We share the enthusiasm shown by the investment community in the UK for this important day. The reaction we have seen since we published our prospectus two weeks ago has been overwhelming. With the support of the FCA and London Stock Exchange, the medical cannabis industry is set to take off in the UK and in Europe, similar to what’s happened in North America in recent times. This is just the beginning”.
If you do nothing else this evening then listen to this podcast.
www.share-talk.com/avihu-tamir-ceo-of-kanabo-group-plc-knb-l-first-day-of-dealings-interview/
Highlights
– The Company has raised gross proceeds of £6 million through an oversubscribed fundraising;
– Kanabo Research Limited has the only medically-approved vaporisation device, the VapePod®, which provides metered dosages of its proprietary cannabis-based oil formulations;
– Kanabo is already engaged in selling its products as part of a Pilot Scheme and expects to soon be ready to scale up its sales;
– Kanabo’s products are triple-tested for safety, and Kanabo has plans for further safety and efficacy testing on their products;
– Use of Proceeds for the next 12 months include sales & marketing and research & development.
Upon Admission, the Company will acquire Kanabo Research Limited for an initial consideration of £15 million. The initial consideration is being satisfied by the issue of 230,769,210 new ordinary shares in the Company. In conjunction with Admission, the Company has raised gross proceeds of £6.0 million through an oversubscribed fundraising that is comprised of a placing and subscription, at an issue price of 6.5 pence per share. Upon Admission, the Company will have a market capitalisation (at the issue price) of approximately £23.4 million. Peterhouse Capital Limited acted as Broker and SI Capital Limited as Placing Agent to this fundraising.
Avihu Tamir, CEO of Kanabo Group Plc, says:
“We are proud and happy to be listed on London Stock Exchange. I would like to thank Spinnaker Opportunities and the whole transaction team for helping us to reach this goal and to thank new and existing shareholders who have invested in our pioneering endeavour.
We share the enthusiasm shown by the investment community in the UK for this important day. The reaction we have seen since we published our prospectus two weeks ago has been overwhelming. With the support of the FCA and London Stock Exchange, the medical cannabis industry is set to take off in the UK and in Europe, similar to what’s happened in North America in recent times. This is just the beginning”.
You can buy on II (Interactive Investor) but you must use the telephone trading option.
I managed to buy my holding using II (Interactive Investor)
But i had to telephone them and hold for approx 30 minutes in all.
However, what is 30 minutes to ensure you get your stock.
I also had to go to "Market best" something I never normally do, but consider this isnt available online yet when it does it could go stratospheric.
I managed to buy my holding using II (Interactive Investor)
But i had to telephone them and hold for approx 30 minutes in all.
However, what is 30 minutes to ensure you get your stock.
I also had to go to "Market best" something I never normally do, but consider this isnt available online yet when it does it could go stratospheric.
I managed to buy my holding using II (Interactive Investor)
But i had to telephone them and hold for approx 30 minutes in all.
However, what is 30 minutes to ensure you get your stock.
I also had to go to "Market best" something I never normally do, but consider this isnt available online yet when it does it could go stratospheric.
Metered doses in a Vape.... Hallelujah...
CBD and THC metered out in medicinal known qtys..
I had to telephone II to secure my KNB stock.
I certainly feel it will be worth it as majority of trading platforms are not trading it yet.
Once it does then it becomes more widely available and demand can be satisfied.
I consider myself lucky to have secured a holding of MXC, and for me it was easy.
However I have really had to ring around for my KNB stock, but eventually got them.
Using Interactive Investor and placing a telephone trade at "Market best"..
I foresee rises galore between the two, but just like i said last week regards quick news here on MXC, expect the same with KNB... They will have positive news in the line, and i suspect we will wont be waiting to long.
Buy KNB
Buy MXC
Couldn't wait to get in on these, and despite not being able to trade online, I eventually secured mine via the telephone after waiting 30 minutes using Interactive Investor.
The Raft of not good, but GREAT news emanating from PFC.
www.petrofac.com/en-gb/media/news/
www.petrofac.com/en-gb/media/news/
A new alliance has been formed giving North Sea oil firms a quicker and cheaper means of developing their fields using platforms owned by Repsol Sinopec Resources UK (RSRUK).
The Aberdeen-headquartered firm has joined forces with energy service giants TechnipFMC and Petrofac to lay on an “an integrated, technically robust and commercially flexible solution”.
The trio are seeking to maximise the recovery of oil and gas from the UK Continental Shelf (UKCS).
RSRUK, a Spanish-Chinese joint venture, said it was providing access to its facilities under the “industry-led infrastructure code of practice”.
The company will be hoping to prolong the production life of assets in its portfolio, which contains some of the most mature platforms on the UKCS.
TechnipFMC will deploy its “iFEED” front-end engineering and design service and its integrated subsea business model, iEPCI.
For its part, Petrofac will provide all topsides engineering and operations support.
RSRUK chief executive Jose Luis Munoz said the industry had to get better at recognising the benefits of utilising existing North Sea infrastructure to deliver more barrels and minimise carbon emissions.
Mr Munoz added: “This industry collaboration brings together three well respected, experienced companies that have the resources, drive and ambition to support the continued success of the industry for many years to come.”
Nick Shorten, managing director of Petrofac’s engineering and production services, west business, said: “With more than three billion barrels locked in marginal fields across the UKCS, small pools represent a big opportunity.
“Industry level collaborations such as this will drive the standardisation required to reduce the time and cost of tie-back developments.
“Petrofac is thrilled to combine the asset knowledge gained as Repsol Sinopec’s operations and maintenance partner, with our engineering and project management expertise in support of this exciting collaboration.”
Jonathan Landes, president subsea, TechnipFMC, said: “We are delighted to play a part in helping to maximise recovery of oil and gas from the UK Continental Shelf.
“Leveraging our integrated subsea business models, iFEED and iEPCI, we are ideally placed to support and optimise future development opportunities from early concept to first production and beyond while minimising the carbon footprint.
“With a shared commitment to excellence in Health, Safety, Environmental and Quality standards, we look forward to working with Repsol Sinopec to deliver a culture of efficiency, standardisation and sharing of best practice as we adopt this unique and important alliance in the UK.”
Exactly my thoughts SEA7
It could be something as simple as illness. (After all we are in the midst of a pandemic)
Lots of supposition, but cutting through the weird and fantastical, I think the options with legs are illness, or KBR implications..
The sentence would have been agreed by SFO, Lufkin, Courts prior to sentence day. (After all that will be the reason he coughed to 3 further charges)
Adjournment of sentencing is actually pretty interesting.
Did Lufkin cough and admit his guilt when confronted by the SFO material that thanks to KBR would now be inadmissible????
If so then "These boots are made for walking, and that's just what they'll do"
It could also be because of Illness (As mentioned)
Its all good fun, and I am really hopeful the SFO are going to have to climb down... :-)
I thought Ammu was the Judge.... LOL
Agreed to the extent that it will fly if SFO announce cessation of pursuing PFC, but they cannot fine PFC anything, not even a penny as they have not charged PFC with anything...